Table 4.
Comparison of diagnostic performance of the three‐Glu‐peptide panel, AFP level, and combined model for discriminating early stage HCC from stratified controls
| Diagnostic Performance | Very Early Stage HCC (BCLC 0) | Early Stage HCC (BCLC 0 and A) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (n = 36) | (n = 159) | |||||||||||||||
| AUROC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (95% CI) | AUROC (95% CI) | Sensitivity (%) | Specificity (%) | PPV (%) | NPV (%) | Accuracy (95% CI) | |||||
| Controls (n = 134) | P value | P value | ||||||||||||||
| DCP three‐Glu‐peptide panel | 0.825 | 36.1 | 95.5 | 68.4 | 84.8 | 0.829 | 0.794 | 38.4 | 95.5 | 91.0 | 56.6 | 0.645 | ||||
| (0.748‐0.902) | (0.764‐0.883) | (0.744‐0.845) | (0.587‐0.700) | |||||||||||||
| AFP value | 0.764 | 0.376 | * | 50.0 | 91.8 | 62.1 | 87.2 | 0.829 | 0.754 | 0.293 | * | 44.7 | 91.8 | 86.6 | 58.3 | 0.662 |
| (0.659‐0.869) | (0.764‐0.883) | (0.698‐0.811) | (0.605‐0.716) | |||||||||||||
| DCP three‐Glu‐peptide panel + AFP value | 0.896 | <0.05 | † | 69.4 | 90.3 | 65.8 | 91.7 | 0.859 | 0.864 | <0.05 | † | 64.8 | 90.3 | 88.8 | 68.4 | 0.765 |
| (0.840‐0.953) | (0.797‐0.907) | (0.823‐0.906) | (0.712‐0.812) | |||||||||||||
| CHB with no LC (n = 92) | P valve | P value | ||||||||||||||
| DCP three‐Glu‐peptide panel | 0.835 | 36.1 | 97.8 | 86.7 | 79.7 | 0.805 | 0.803 | 38.4 | 97.8 | 96.8 | 47.9 | 0.602 | ||||
| (0.755‐0.915) | (0.725‐0.869) | (0.750‐0.857) | (0.538‐0.663) | |||||||||||||
| AFP value | 0.793 | 0.547 | * | 50.0 | 93.5 | 75.0 | 82.7 | 0.813 | 0.787 | 0.686 | * | 44.7 | 93.5 | 92.2 | 49.4 | 0.626 |
| (0.731‐0.844) | (0.734‐0.876) | (0.731‐0.844) | (0.562‐0.686) | |||||||||||||
| DCP three‐Glu‐peptide panel + AFP value | 0.915 | <0.05 | † | 69.4 | 94.6 | 83.3 | 88.8 | 0.875 | 0.884 | <0.05 | † | 64.8 | 94.6 | 95.4 | 60.8 | 0.757 |
| (0.861‐0.969) | (0.805‐0.927) | (0.842‐0.926) | (0.699‐0.809) | |||||||||||||
| CHC with no LC (n = 13) | P value | P value | ||||||||||||||
| DCP three‐Glu‐peptide panel | 0.729 | 36.1 | 84.6 | 86.7 | 32.4 | 0.490 | 0.687 | 38.4 | 84.6 | 96.8 | 10.1 | 0.419 | ||||
| (0.557‐0.900) | (0.344‐0.637) | (0.536‐0.837) | (0.344‐0.496) | |||||||||||||
| AFP value | 0.682 | 0.683 | * | 50.0 | 100.0 | 100.0 | 41.9 | 0.813 | 0.663 | 0.799 | * | 44.7 | 100.0 | 100.0 | 12.9 | 0.488 |
| (0.537‐0.846) | (0.734‐0.876) | (0.574‐0.753) | (0.412‐0.566) | |||||||||||||
| DCP three‐Glu‐peptide panel + AFP value | 0.840 | <0.05 | † | 69.4 | 84.6 | 92.6 | 50.0 | 0.735 | 0.801 | <0.05 | † | 64.8 | 84.6 | 98.1 | 16.4 | 0.663 |
| (0.714‐0.965) | (0.589‐0.851) | (0.691‐0.911) | (0.587‐0.733) | |||||||||||||
| LC (n = 29) | P value | P value | ||||||||||||||
| DCP three‐Glu‐peptide panel | 0.835 | 36.1 | 93.1 | 86.7 | 54.0 | 0.615 | 0.816 | 38.4 | 93.1 | 96.8 | 21.6 | 0.468 | ||||
| (0.731‐0.939) | (0.486‐0.734) | (0.723‐0.909) | (0.723‐0.909) | |||||||||||||
| AFP value | 0.707 | 0.140 | * | 50.0 | 82.8 | 78.3 | 57.1 | 0.646 | 0.691 | 0.074 | * | 44.7 | 82.8 | 93.4 | 21.4 | 0.505 |
| (0.576‐0.838) | (0.518‐0.761) | (0.591‐0.791) | (0.432‐0.579) | |||||||||||||
| DCP three‐Glu‐peptide panel + AFP value | 0.861 | 0.533 | † | 69.4 | 79.3 | 80.7 | 67.7 | 0.739 | 0.831 | 0.650 | † | 64.8 | 79.3 | 94.5 | 29.1 | 0.670 |
| (0.769‐0.953) | (0.615‐0.840) | (0.749‐0.914) | (0.598‐0.737) | |||||||||||||
*
DCP three‐Glu‐peptide panel versus AFP level.
†
DCP three‐Glu‐peptide panel with versus without AFP level. No significant differences were found between the AUROC values of each panel for distinguishing very early stage or early stage HCC from stratified control subgroups and the entire control group (DeLong`s test, P > 0.05).
Abbreviations: NPV, negative predictive value; PPV, positive predictive value.